Commonwealth of Pennsylvania Public School Empls Retrmt SYS Increases Stake in TG Therapeutics, Inc. $TGTX

Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 1,221.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 422,078 shares of the biopharmaceutical company’s stock after purchasing an additional 390,137 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in TG Therapeutics were worth $15,191,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Strs Ohio purchased a new position in shares of TG Therapeutics in the 1st quarter valued at about $785,000. KLP Kapitalforvaltning AS lifted its holdings in TG Therapeutics by 7.7% in the second quarter. KLP Kapitalforvaltning AS now owns 30,800 shares of the biopharmaceutical company’s stock valued at $1,108,000 after acquiring an additional 2,200 shares during the period. Yorktown Management & Research Co Inc purchased a new position in TG Therapeutics in the second quarter valued at about $383,000. United Services Automobile Association acquired a new stake in TG Therapeutics in the first quarter valued at $340,000. Finally, Mackenzie Financial Corp grew its position in shares of TG Therapeutics by 75.4% in the first quarter. Mackenzie Financial Corp now owns 15,587 shares of the biopharmaceutical company’s stock valued at $615,000 after purchasing an additional 6,699 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. B. Riley raised shares of TG Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 4th. JPMorgan Chase & Co. increased their price objective on shares of TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. HC Wainwright began coverage on TG Therapeutics in a research report on Monday, October 6th. They issued a “buy” rating and a $60.00 target price on the stock. Wall Street Zen raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $50.25.

TG Therapeutics Trading Up 0.1%

NASDAQ TGTX opened at $31.00 on Monday. TG Therapeutics, Inc. has a 1-year low of $25.28 and a 1-year high of $46.48. The firm’s fifty day simple moving average is $33.90 and its 200-day simple moving average is $34.23. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $4.92 billion, a PE ratio of 83.78 and a beta of 1.95.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $2.19. The business had revenue of $161.71 million during the quarter, compared to the consensus estimate of $152.12 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. TG Therapeutics’s quarterly revenue was up 92.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.02 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the company’s stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the sale, the director directly owned 94,061 shares of the company’s stock, valued at approximately $3,032,526.64. This represents a 18.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 10.64% of the stock is owned by company insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.